OTC Watch

All stocks / CERO

CERO THERAPEUTICS HOLDINGS, INC. CERO

CERO Therapeutics Holdings (CERO): shares outstanding up 295% in a year, convertible notes mentioned in an 8-K in May 2026, a late 10-K notice in April 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

DilutionEstimated floatCostly financingLate filing OTCQBCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
CERO THERAPEUTICS HOLDINGS INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Website
www.cero.bio
Source: Stockwatch, 2026-11-17

News headlines

CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial
2026-11-03 08:15 · News Release
CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
2026-10-26 17:22 · News Release
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
2026-10-26 09:05 · News Release
CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers
2026-10-26 09:00 · News Release
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
2026-10-07 15:00 · News Release
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
2026-08-31 07:30 · News Release
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
2026-06-15 08:15 · News Release
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
2026-05-11 08:15 · News Release
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-04-14 08:15 · News Release
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-03-30 08:15 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($19,920,262)
What it means

It spends more than it earns

Under strain

The company lost $19.9 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$1,700,000
Net cash used in operating activities
($16,100,000)
What it means

The cash could run out soon

Under strain

It had $1.7 million in the bank and used about $1.3 million a month. At that pace the money lasts about 1 months unless it borrows or sells more shares.

The report says
Total assets
$3,641,134
Total liabilities
$9,087,596
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $3.6 million. Its debts and unpaid bills add up to $9.1 million. That is about $2.50 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-11-13

Shares outstanding rose from 21,102,671 (2025-11-19) to 83,309,742 (2026-11-13), up 295%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-11-13

Estimated float about 83,309,742 shares as of 2026-11-13: 83,309,742 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-05-29

8-K filed 2026-05-29 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-05-01

8-K filed 2026-05-01 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-04-14

8-K filed 2026-04-14 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Late filing2026-04-01

Filed NT 10-K on 2026-04-01: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Costly financing2026-03-11

8-K filed 2026-03-11 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-02-13

8-K filed 2026-02-13 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2025-12-02

8-K filed 2025-12-02 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Late filing2025-11-17

Filed NT 10-Q on 2025-11-17: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Shares outstanding

Source: SEC filings
2025-04-24
5.6M
2025-05-14
7.7M
2025-08-21
1.2M
2025-11-19
21.1M
2026-04-14
36.8M
2026-05-14
45.1M
2026-08-13
71.6M
2026-11-13
83.3M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-13 10-QQUARTERLY REPORT
2026-10-07 8-KCURRENT REPORT
2026-08-31 8-KCURRENT REPORT
2026-08-14 SCHEDULE 13G/A
2026-08-14 10-QQUARTERLY REPORT
2026-08-14 424B3PROSPECTUS SUPPLEMENT
2026-07-17 8-KCURRENT REPORT
2026-07-17 424B3PROSPECTUS SUPPLEMENT
2026-07-13 25-NSE
2026-06-26 8-KCURRENT REPORT
2026-06-26 424B3PROSPECTUS SUPPLEMENT
2026-05-29 8-KCURRENT REPORT

Common questions about CERO

Does CERO file reports with the SEC?

Yes. CERO Therapeutics Holdings files with the SEC under company number 0001870404. The most recent filing we hold is a 10-Q dated 2026-11-13.

Source record

How many CERO shares are outstanding?

83,309,742 shares as of 2026-11-13, as reported to the SEC. That is up 295% from 21,102,671 on 2025-11-19.

Source record

Has CERO filed reports late?

Yes. In the last 12 months it filed 2 late-filing notices, most recently a NT 10-K on 2026-04-01. A notice means a report was not ready on time; check whether the report followed.

Source record

Who runs CERO Therapeutics Holdings?

Officers named in its insider filings: Christopher B Ehrlich (Chairman and CEO), Andrew Albert Kucharchuk (Chief Financial Officer) and Kristen Pierce (Chief Development Officer).

Source record

Is CERO Therapeutics Holdings making money?

The company lost $19.9 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record